Global Meningococcal Infections Vaccine Market Intelligence Report (2026–2036)
Market Overview
The global meningococcal infections vaccine market was valued at USD xxxx million in 2025 and is projected to reach USD xxxx million by 2036, expanding at a CAGR of xx%. The market is driven by increasing awareness of meningococcal disease, government immunization programs, and technological advancements in vaccine development.
The report integrates both primary and secondary research methodologies, analyzing government policies, competitive dynamics, historical data, current market trends, and innovations shaping the industry.
Impact of COVID-19
The COVID-19 pandemic disrupted vaccine supply chains and clinical trials in 2020, delaying immunization campaigns worldwide. However, it also accelerated investments in vaccine R&D, manufacturing infrastructure, and global health preparedness, indirectly benefiting the meningococcal vaccine market in the long term.
Market Segmentation
By Type
- Meningococcal Conjugate Vaccines (MCV)
- Meningococcal Polysaccharide Vaccines (MPV)
- Serogroup B Meningococcal Vaccines (MenB)
- Combination Vaccines (MenACWY + Hib, etc.)
- Next-generation recombinant vaccines
By Application
- Children (0–12 years)
- Preteens/Teens (13–18 years)
- Adults (19+ years)
- High-risk populations (travelers, military, immunocompromised)
Regional Analysis
- North America: Strong government immunization mandates, high awareness, presence of major players.
- Europe: Widespread adoption of conjugate vaccines, strong regulatory frameworks, rising MenB uptake.
- Asia-Pacific: Rapid population growth, increasing healthcare expenditure, government vaccination drives in China & India.
- South America: Expanding immunization programs, growing partnerships with global vaccine manufacturers.
- Middle East & Africa: High disease burden, WHO-supported vaccination campaigns, reliance on imports.
Key Players
- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Pfizer Inc.
- Novartis Vaccines (legacy portfolio)
- Beijing Tiantan Biological Products
- Wuhan Institute of Biological Products
- Lanzhou Institute of Biological Products
- Hualan Biological Engineering
- Chongqing Zhifei Biological Products
- Zhejiang Tianyuan Bio-Pharmaceutical
- Walvax Biotechnology
- Royal (Wuxi) Bio-Pharmaceutical
- Serum Institute of India
- Bharat Biotech
- CSL Limited (Seqirus)
Porter’s Five Forces Analysis
- Threat of New Entrants: Moderate – high R&D costs and regulatory barriers.
- Bargaining Power of Suppliers: Moderate – limited suppliers for raw materials and adjuvants.
- Bargaining Power of Buyers: High – governments and NGOs negotiate bulk procurement.
- Threat of Substitutes: Low – few alternatives to vaccines for prevention.
- Industry Rivalry: High – intense competition among multinational and regional players.
SWOT Analysis
Strengths
- Established immunization programs
- Strong pipeline of conjugate and recombinant vaccines
- Global health organization support
Weaknesses
- High production costs
- Cold-chain dependency
- Limited awareness in low-income regions
Opportunities
- Expansion in emerging markets
- Technological innovation (DNA/RNA-based vaccines)
- Strategic collaborations and licensing agreements
Threats
- Stringent regulatory approvals
- Vaccine hesitancy in certain regions
- Supply chain disruptions
Trend Analysis
- Rising demand for MenB vaccines in Europe and North America.
- Increasing adoption of quadrivalent conjugate vaccines (MenACWY).
- Growth in public-private partnerships for vaccine distribution.
- Advances in mRNA and recombinant vaccine technologies.
- Expansion of travel-related vaccination requirements.
Drivers
- Rising global incidence of meningococcal infections.
- Government immunization mandates and funding.
- Technological advancements in vaccine formulations.
- Increasing awareness campaigns by WHO and UNICEF.
Challenges
- High R&D and production costs.
- Cold-chain logistics in developing regions.
- Regulatory complexities across geographies.
- Vaccine hesitancy and misinformation.
Value Chain Analysis
- Raw Materials & Inputs – adjuvants, antigens, stabilizers.
- Manufacturing & Formulation – biopharma companies, contract manufacturers.
- Distribution & Logistics – cold-chain providers, wholesalers.
- End Users – hospitals, clinics, government immunization programs.
- Support Ecosystem – NGOs, WHO, UNICEF, public health agencies.
Quick Recommendations for Stakeholders
- Manufacturers: Invest in next-gen recombinant and mRNA-based vaccines to stay competitive.
- Governments: Expand immunization programs in emerging markets with subsidies and awareness campaigns.
- Investors: Focus on companies with strong pipelines and global distribution networks.
- Healthcare Providers: Strengthen outreach and education to reduce vaccine hesitancy.
- NGOs & Global Health Agencies: Partner with regional players to improve access in low-income countries.
Explore more reports here-
https://westernmarketresearch.com/reports
1. Market Overview of Meningococcal Infections Vaccine
1.1 Meningococcal Infections Vaccine Market Overview
1.1.1 Meningococcal Infections Vaccine Product Scope
1.1.2 Market Status and Outlook
1.2 Meningococcal Infections Vaccine Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Meningococcal Infections Vaccine Historic Market Size by Regions
1.4 Meningococcal Infections Vaccine Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Meningococcal Infections Vaccine Sales Market by Type
2.1 Global Meningococcal Infections Vaccine Historic Market Size by Type
2.2 Global Meningococcal Infections Vaccine Forecasted Market Size by Type
2.3 Meningococcal conjugate vaccines
2.4 Meningococcal polysaccharide vaccine
2.5 Serogroup B meningococcal vaccine
3. Covid-19 Impact Meningococcal Infections Vaccine Sales Market by Application
3.1 Global Meningococcal Infections Vaccine Historic Market Size by Application
3.2 Global Meningococcal Infections Vaccine Forecasted Market Size by Application
3.3 For Children
3.4 For Preteens/Teens
3.5 For Adults
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Meningococcal Infections Vaccine Production Capacity Market Share by Manufacturers
4.2 Global Meningococcal Infections Vaccine Revenue Market Share by Manufacturers
4.3 Global Meningococcal Infections Vaccine Average Price by Manufacturers
5. Company Profiles and Key Figures in Meningococcal Infections Vaccine Business
5.1 Sanofi-Pasteur
5.1.1 Sanofi-Pasteur Company Profile
5.1.2 Sanofi-Pasteur Meningococcal Infections Vaccine Product Specification
5.1.3 Sanofi-Pasteur Meningococcal Infections Vaccine Production Capacity, Revenue, Price and Gross Margin
5.2 Beijing Tiantan Biological Products
5.2.1 Beijing Tiantan Biological Products Company Profile
5.2.2 Beijing Tiantan Biological Products Meningococcal Infections Vaccine Product Specification
5.2.3 Beijing Tiantan Biological Products Meningococcal Infections Vaccine Production Capacity, Revenue, Price and Gross Margin
5.3 Wuhan Institute of Biological Products
5.3.1 Wuhan Institute of Biological Products Company Profile
5.3.2 Wuhan Institute of Biological Products Meningococcal Infections Vaccine Product Specification
5.3.3 Wuhan Institute of Biological Products Meningococcal Infections Vaccine Production Capacity, Revenue, Price and Gross Margin
5.4 Lanzhou Institute of Biological Products
5.4.1 Lanzhou Institute of Biological Products Company Profile
5.4.2 Lanzhou Institute of Biological Products Meningococcal Infections Vaccine Product Specification
5.4.3 Lanzhou Institute of Biological Products Meningococcal Infections Vaccine Production Capacity, Revenue, Price and Gross Margin
5.5 Hualan Biological Engineering
5.5.1 Hualan Biological Engineering Company Profile
5.5.2 Hualan Biological Engineering Meningococcal Infections Vaccine Product Specification
5.5.3 Hualan Biological Engineering Meningococcal Infections Vaccine Production Capacity, Revenue, Price and Gross Margin
5.6 Chongqing Zhifei Biological Products
5.6.1 Chongqing Zhifei Biological Products Company Profile
5.6.2 Chongqing Zhifei Biological Products Meningococcal Infections Vaccine Product Specification
5.6.3 Chongqing Zhifei Biological Products Meningococcal Infections Vaccine Production Capacity, Revenue, Price and Gross Margin
5.7 Zhejiang Tianyuan Bio-Pharmaceutical
5.7.1 Zhejiang Tianyuan Bio-Pharmaceutical Company Profile
5.7.2 Zhejiang Tianyuan Bio-Pharmaceutical Meningococcal Infections Vaccine Product Specification
5.7.3 Zhejiang Tianyuan Bio-Pharmaceutical Meningococcal Infections Vaccine Production Capacity, Revenue, Price and Gross Margin
5.8 Walvax Biotechnology
5.8.1 Walvax Biotechnology Company Profile
5.8.2 Walvax Biotechnology Meningococcal Infections Vaccine Product Specification
5.8.3 Walvax Biotechnology Meningococcal Infections Vaccine Production Capacity, Revenue, Price and Gross Margin
5.9 Royal(Wuxi) Bio-Pharmaceutical
5.9.1 Royal(Wuxi) Bio-Pharmaceutical Company Profile
5.9.2 Royal(Wuxi) Bio-Pharmaceutical Meningococcal Infections Vaccine Product Specification
5.9.3 Royal(Wuxi) Bio-Pharmaceutical Meningococcal Infections Vaccine Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Meningococcal Infections Vaccine Market Size
6.2 North America Meningococcal Infections Vaccine Key Players in North America
6.3 North America Meningococcal Infections Vaccine Market Size by Type
6.4 North America Meningococcal Infections Vaccine Market Size by Application
7. East Asia
7.1 East Asia Meningococcal Infections Vaccine Market Size
7.2 East Asia Meningococcal Infections Vaccine Key Players in North America
7.3 East Asia Meningococcal Infections Vaccine Market Size by Type
7.4 East Asia Meningococcal Infections Vaccine Market Size by Application
8. Europe
8.1 Europe Meningococcal Infections Vaccine Market Size
8.2 Europe Meningococcal Infections Vaccine Key Players in North America
8.3 Europe Meningococcal Infections Vaccine Market Size by Type
8.4 Europe Meningococcal Infections Vaccine Market Size by Application
9. South Asia
9.1 South Asia Meningococcal Infections Vaccine Market Size
9.2 South Asia Meningococcal Infections Vaccine Key Players in North America
9.3 South Asia Meningococcal Infections Vaccine Market Size by Type
9.4 South Asia Meningococcal Infections Vaccine Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Meningococcal Infections Vaccine Market Size
10.2 Southeast Asia Meningococcal Infections Vaccine Key Players in North America
10.3 Southeast Asia Meningococcal Infections Vaccine Market Size by Type
10.4 Southeast Asia Meningococcal Infections Vaccine Market Size by Application
11. Middle East
11.1 Middle East Meningococcal Infections Vaccine Market Size
11.2 Middle East Meningococcal Infections Vaccine Key Players in North America
11.3 Middle East Meningococcal Infections Vaccine Market Size by Type
11.4 Middle East Meningococcal Infections Vaccine Market Size by Application
12. Africa
12.1 Africa Meningococcal Infections Vaccine Market Size
12.2 Africa Meningococcal Infections Vaccine Key Players in North America
12.3 Africa Meningococcal Infections Vaccine Market Size by Type
12.4 Africa Meningococcal Infections Vaccine Market Size by Application
13. Oceania
13.1 Oceania Meningococcal Infections Vaccine Market Size
13.2 Oceania Meningococcal Infections Vaccine Key Players in North America
13.3 Oceania Meningococcal Infections Vaccine Market Size by Type
13.4 Oceania Meningococcal Infections Vaccine Market Size by Application
14. South America
14.1 South America Meningococcal Infections Vaccine Market Size
14.2 South America Meningococcal Infections Vaccine Key Players in North America
14.3 South America Meningococcal Infections Vaccine Market Size by Type
14.4 South America Meningococcal Infections Vaccine Market Size by Application
15. Rest of the World
15.1 Rest of the World Meningococcal Infections Vaccine Market Size
15.2 Rest of the World Meningococcal Infections Vaccine Key Players in North America
15.3 Rest of the World Meningococcal Infections Vaccine Market Size by Type
15.4 Rest of the World Meningococcal Infections Vaccine Market Size by Application
16 Meningococcal Infections Vaccine Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Market Segmentation
By Type
- Meningococcal Conjugate Vaccines (MCV)
- Meningococcal Polysaccharide Vaccines (MPV)
- Serogroup B Meningococcal Vaccines (MenB)
- Combination Vaccines (MenACWY + Hib, etc.)
- Next-generation recombinant vaccines
By Application
- Children (0–12 years)
- Preteens/Teens (13–18 years)
- Adults (19+ years)
- High-risk populations (travelers, military, immunocompromised)
Regional Analysis
- North America: Strong government immunization mandates, high awareness, presence of major players.
- Europe: Widespread adoption of conjugate vaccines, strong regulatory frameworks, rising MenB uptake.
- Asia-Pacific: Rapid population growth, increasing healthcare expenditure, government vaccination drives in China & India.
- South America: Expanding immunization programs, growing partnerships with global vaccine manufacturers.
- Middle East & Africa: High disease burden, WHO-supported vaccination campaigns, reliance on imports.
Key Players
- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Pfizer Inc.
- Novartis Vaccines (legacy portfolio)
- Beijing Tiantan Biological Products
- Wuhan Institute of Biological Products
- Lanzhou Institute of Biological Products
- Hualan Biological Engineering
- Chongqing Zhifei Biological Products
- Zhejiang Tianyuan Bio-Pharmaceutical
- Walvax Biotechnology
- Royal (Wuxi) Bio-Pharmaceutical
- Serum Institute of India
- Bharat Biotech
- CSL Limited (Seqirus)
